Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 10/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
| ▸ | FPR1 | P21462 | 4/20 | 0.38 |
| ▸ | FPR2 | P25090 | 4/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 1/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19544843 | 1.00 | CTSC (0.40) | CTSCKCNH2CTSKFPR1FPR2 | |
| SCHEMBL22582613 | 1.00 | CTSC (0.40) | CTSCKCNH2CTSKFPR1FPR2 | |
| SCHEMBL19521201 | 0.89 | CTSC (0.42) | CTSCKCNH2CTSKFPR1FPR2 | |
| SCHEMBL19521205 | 0.89 | CTSC (0.42) | CTSCKCNH2CTSKFPR1FPR2 | |
| SCHEMBL19544840 | 0.85 | YAP1 (0.39) | CTSCCTSKFPR1FPR2 | |
| SCHEMBL19544844 | 0.85 | YAP1 (0.39) | CTSCCTSKFPR1FPR2 | |
| SCHEMBL19521207 | 0.83 | SLC6A3 (0.36) | CTSCKCNH2CTSKHSD11B1 | |
| SCHEMBL19544833 | 0.75 | CHRM3 (0.38) | CTSCFPR1FPR2CHRM3DPP4 | |
| SCHEMBL19544841 | 0.75 | CTSC (0.69) | CTSCKCNH2CTSKFPR1FPR2 | |
| SCHEMBL19544837 | 0.73 | PIN1 (0.38) | FPR1FPR2CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339562-A1 | COVALENT BTK INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2020-10-29 | — | — | US | disclosed |
| US-20200339562-A1 | COVALENT BTK INHIBITORS AND USES THEREOF | MIDCAP FINANCIAL TRUST | 2020-10-29 | — | — | US | disclosed |
| WO-2017190048-A1 | COVALENT BTK INHIBITORS AND USES THEREOF | X-CHEM, INC. (US) | 2017-11-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200339562-A1 | COVALENT BTK INHIBITORS AND USES THEREOF | BTK, SYK, LYN | CTSC 620/4885KCNH2 2703/4885CTSK 1208/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.